Clinical trials in various settings have revealed that HLA-A2-restricted PSMA peptides elicit cytotoxic T cell lymphocyte (CTL) responses with antitumor characteristics in vitro [36,37,38,39], while in-vitro and xenograft studies have examined the possibility of PSMA as an immunotherapeutic molecule by studying the effects of antibodies targeting PSMA-expressing PCa tumor cells [40,41,42,43]. The gene discussed is FOLH1; the disease is neoplasm.